CAPTRUST Financial Advisors
GENE

CAPTRUST Financial Advisors’s Genetic Technologies Ltd. GENE Stock Holding History

CAPTRUST Financial Advisors’s Portfolio GENE Stock Details GENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-700
Closed -$4K – 4307
2022
Q2 		$4K Hold
700
– – ﹤0.01% 4236
2022
Q1 		$7K Hold
700
– – ﹤0.01% 4014
2021
Q4 		$7K Buy
+700
New +$8.97K ﹤0.01% 3942

Other funds holding GENE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CA
Cetera Advisors Denver, Colorado $12.7B AUM 22.7% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CAPTRUST Financial Advisors's GENE Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Genetic Technologies Ltd. (GENE) in Q3 2022, closing a stake of 700 shares — an estimated $4K sold.

CAPTRUST Financial Advisors first reported a position in GENE in Q4 2021 and held it in 3 quarters. The position peaked at $7K in Q1 2022. 10 funds tracked by Wall St. Rank hold GENE as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Genetic Technologies Ltd. position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 700 Genetic Technologies Ltd. shares in Q3 2022, an estimated $4K.
  • CAPTRUST Financial Advisors first reported a position in Genetic Technologies Ltd. in Q4 2021 and held it in 3 quarters.
  • CAPTRUST Financial Advisors's Genetic Technologies Ltd. position peaked at $7K in Q1 2022.
  • 10 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.